StockWatch
·

MARKSANS PHARMA LTD.

BSE: 524404

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
371.05
+9.6%-2.0%
Expenditure
270.83
+9.1%+5.3%
Net Profit
85.54
+23.9%-14.3%
OPM %
16.68%
-8.88pp-5.81pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00108.93217.87326.80435.73Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Record growth, margin resilience tested

geographic diversification · Europe acceleration · margin pressure

Result verdictFollow-upQ2 FY2713 Nov 20266 minPharma & Healthcare

Record growth beats guidance, but QoQ PAT decline flags cost pressure

geographic diversification · Europe acceleration · capacity expansion

TranscriptDeep diveQ2 FY2713 Nov 20266 minPharma & Healthcare

Marksans Q2 FY27: consolidated PAT +45% YoY to ₹143.5 Cr, margins ease off Q1's record

pharma generics · margin expansion · europe expansion

ResultsQ2 FY2704 Nov 20263 minPharma & Healthcare
Latest
Board Meeting4 Nov, 1:27 pm

Marksans Q2 FY27: consolidated PAT +45% YoY to ₹143.5 Cr, margins ease off Q1's record

Marksans Pharma's consolidated revenue for the September 2026 quarter rose 30.5% YoY to ₹940.17 Cr (+11.8% QoQ), with consolidated PAT up 44.8% YoY to ₹143.53 Cr (₹141.31 Cr attributable to owners; basic EPS ₹3.12 vs ₹2.17 a year ago). Sequentially, PAT eased 10.0% QoQ against Q1 FY27's record ₹159.41 Cr, and OPM moderated to 22.81% from Q1's 25.34% peak — still up from 20.06% a year ago, so the YoY growth story is intact; this is a sequential cool-off after an unusually strong June quarter, not a reversal. No exceptional items were reported in either the current or comparative periods, so the growth is on a like-for-like basis. Gross margin held near 58.5%, down only marginally from Q1's 59.1% and still well above the 55-56% band management guided as the 'normalized' level for the year — that normalization has not materially shown up yet. NPM (PAT/total income) came in at 14.98%, up from 13.36% YoY but down from Q1's 18.40%, tracking the OPM move. Total expenses were ₹764.82 Cr against total income of ₹958.32 Cr for the quarter. Against management's own FY27 guidance from the August 20, 2026 concall — 15-20% revenue growth and a 20-21% sustainable / 21-22% year-end EBITDA margin band — this quarter's 30.5% YoY revenue growth and 22.81% OPM both run ahead of plan even with the QoQ dip. Gross margin normalization to 55-56% is the one guided metric not yet realized and is now the gap to watch. No Street estimates specific to this quarter were found in a search (the result was announced today), so vsStreet is unknown; management issued no separate press release with this filing beyond the procedural board-outcome letter, so there is no company framing to reconcile against. During the half year the company completed two bolt-on European acquisitions — QliniQ B.V. in the Netherlands (EUR 7.5 million, effective April 1, 2026) and ABCnow GmbH in Germany (EUR 1.1 million, effective July 1, 2026) — consistent with management's stated Europe push (full-year Europe revenue target of ₹180 Cr cited in the prior concall). Standalone (India entity) scale remains far smaller — PBT of just ₹13.71 Cr for the quarter — underscoring that most group profitability now sits in the US/UK/Europe subsidiary structure visible only at the consolidated level.

4 Nov 2026, 01:27 pm

Corporate Events

Board MeetingMARKSANS
2026
4Nov

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingMARKSANS
2026
27Aug

Board Meeting

The 34th Annual General Meeting will be held on Thursday, Au…

BSE Filing ↗
DividendMARKSANS
2026
20Aug

₹0.9 / share

BSE Filing ↗
Board MeetingMARKSANS
2026
12Aug

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingMARKSANS
2026
3Jul

Board Meeting

The Board of Directors considered and approved the 34th Annu…

BSE Filing ↗
Board MeetingMARKSANS
2026
5Feb

Board Meeting

consider and approve quarterly results, consider and approve…

BSE Filing ↗
Board MeetingMARKSANS
2025
13Nov

Board Meeting

consider and approve quarterly results for the Quarter, cons…

BSE Filing ↗
Board MeetingMARKSANS
2025
12Aug

Board Meeting

consider and approve financial results for the quarter, cons…

BSE Filing ↗
Board MeetingMARKSANS
2025
19May

Board Meeting

Consider and approve the Audited Financial Results of the Co…

BSE Filing ↗
Board MeetingMARKSANS
2025
11Feb

Board Meeting

consider and approve unaudited financial results

BSE Filing ↗
Board MeetingMARKSANS
2024
12Nov

Board Meeting

Consider and approve the Unaudited Financial Results

BSE Filing ↗
Board MeetingMARKSANS
2024
13Feb

Board Meeting

Consider and approve the unaudited financial results

BSE Filing ↗
Board MeetingMARKSANS
2023
9Nov

Board Meeting

Consider and approve unaudited financial results of the Comp…

BSE Filing ↗
Board MeetingMARKSANS
2023
11Aug

Board Meeting

Consider and approve the Unaudited Financial Results (both S…

BSE Filing ↗